The GMP Group

The UK biotech sector is a dynamic and rapidly growing industry that plays a vital role in global life sciences innovation. It encompasses a broad range of companies focused on drug discovery, diagnostics, genomics, agricultural biotech, and synthetic biology. With strong academic research institutions, particularly in Oxford, Cambridge, and London, and supportive government policies, the UK has become a hub for biotech startups and scale-ups. Investment in the sector remains robust, with significant venture capital and public funding driving R&D. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) also provides a streamlined regulatory environment, making it attractive for clinical trials and product development.

The GMP Group has expertise in the Design and delivery of projects both small or large scale Biotechnology facilities in the startup area and for the more established clients.

Healthcare and the pharmaceutical industry are closely intertwined sectors that work together to promote public health and treat disease. The healthcare system encompasses medical services provided by professionals and institutions, including hospitals, clinics, and primary care, while the pharmaceutical industry focuses on researching, developing, manufacturing, and marketing medications. Pharmaceutical companies play a critical role in advancing medical science by creating innovative drugs and vaccines, which healthcare providers then use to improve patient outcomes. However, the industry also faces scrutiny from regulators throughout the process of manufacturing, storage and distribution.

The GMPG have been working since it’s incorporation in 1995 to assist our clients in the industry to meet the regulatory requirements and ensure patient safety.

The medical device industry encompasses the design, development, manufacturing, and distribution of instruments, machines, implants, and diagnostic tools used in the prevention, diagnosis, treatment, and monitoring of medical conditions. It includes a wide range of products from simple devices like bandages and thermometers to complex technologies such as pacemakers, robotic surgical systems, and advanced imaging equipment. The industry is highly regulated to ensure safety and effectiveness, with oversight from bodies like the U.S. FDA and the EU’s MDR. Innovation, aging populations, and rising healthcare demands continue to drive growth, making it a critical and dynamic sector within global healthcare.

In this varied and highly complex sector GMPG has been working with clients since the start of the company delivering design and CQV solutions to ensure compliance with regulatory requirements for all products.

Logistics environmental control within the pharmaceutical supply chain is crucial to maintaining the integrity, safety, and efficacy of temperature-sensitive medications. It involves rigorous monitoring and regulation of conditions such as temperature, humidity, and light exposure during storage and transportation. Utilizing technologies like real-time tracking, insulated packaging, and climate-controlled vehicles, companies ensure compliance with Good Distribution Practices (GDP) and regulatory standards set by agencies like the FDA and EMA. Effective environmental control minimizes the risk of product degradation, reduces waste, and safeguards public health by ensuring that pharmaceuticals reach end-users in optimal condition.

The GMP Group has many years' experience in designing buildings, environmental control and monitoring systems for Distribution Centers and Facility Warehouses in the Pharma Industry.

GMPG are experts in the Commissioning, Qualification and Validation of all aspects of the supply chain from buildings to modes of transport.ensuring compliance throughout the process.

Laboratory design in the pharmaceutical industry prioritizes functionality, safety, and compliance with stringent regulatory standards such as GMP (Good Manufacturing Practice). The layout must support efficient workflow, minimize cross-contamination risks, and facilitate both research and quality control processes. Key considerations include proper zoning for different activities (e.g., synthesis, analysis, microbiology), use of high-grade materials for surfaces and equipment to ensure cleanliness, and integration of robust ventilation and waste management systems. Additionally, flexibility in design is critical to accommodate evolving technologies and regulatory updates, ensuring long-term viability and operational efficiency.

The GMP Group has extensive knowledge in the Development and QC Functions of Laboratories in the Pharma Industry, ensuring full GLP/GMP Compliance, whilst always ensuring health and safety of the laboratory staff

The Advanced Therapy Medicinal Products (ATMP) sector in the UK is a rapidly growing and strategically important area of biopharmaceutical innovation, encompassing gene therapies, somatic-cell therapies, and tissue-engineered products. Supported by a strong academic base, world-leading research institutions, and initiatives such as the Cell and Gene Therapy Catapult, the UK has positioned itself as a global leader in ATMP development and commercialization. Regulatory support from the Medicines and Healthcare products Regulatory Agency (MHRA) and early patient access schemes have further fostered growth. The sector plays a key role in the UK’s life sciences strategy, attracting significant investment and driving cutting-edge treatments for rare and chronic diseases.

For several years now GMPG have been operating within this area supplying design and CQV services, in particular to the startup companies operating within the UK.

The medicinal cannabis industry has rapidly evolved into a significant global sector, driven by growing recognition of cannabis’s therapeutic benefits in managing conditions such as chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea. Legalization trends across North America, Europe, and parts of Latin America and Asia have fueled investment, research, and development, leading to a surge in pharmaceutical-grade cannabis products. Regulatory frameworks vary widely, influencing market dynamics and access to treatment. Despite ongoing stigma and regulatory challenges, the industry is expected to expand steadily as clinical evidence increases and patient demand grows, positioning medicinal cannabis as a transformative component of modern healthcare.

The GMPG has been working with clients, regulators and law enforcement agencies to design and ensure compliance in the growing and extraction facilities over the last 10 years. A number of these facilities are now fully operational.

Diagnostics in the pharmaceutical industry play a critical role in disease detection, patient stratification, and treatment monitoring, enabling more precise and personalized medicine. These tools help identify biomarkers, assess drug efficacy, and predict adverse reactions, improving the success rate of clinical trials and guiding therapeutic decisions. Companion diagnostics, in particular, are increasingly integrated with targeted therapies to ensure drugs are administered to patients most likely to benefit. As the industry shifts toward precision medicine, diagnostics are becoming essential in streamlining drug development, reducing costs, and enhancing patient outcomes.

The GMP Group has extensive knowledge in the Development and QC Functions of Laboratories in the Pharma Industry, ensuring full GLP/GMP Compliance, and the health and safety of the lab staff.

SAPO (Specified Animal Pathogens Order) licensed high containment facilities in the pharmaceutical industry are specialized laboratories authorized to handle and research specified animal pathogens that pose a risk to animal or public health. These facilities are designed to meet stringent biosafety and biosecurity standards, often at containment levels 3 or 4, to prevent the release of infectious agents. They are critical for the development of veterinary vaccines, diagnostics, and therapeutic products, especially for zoonotic diseases. Compliance with SAPO regulations, overseen by government bodies such as the UK's Department for Environment, Food & Rural Affairs (DEFRA), ensures the safe containment, transport, and disposal of hazardous biological materials.

The GMPG have over many years built up their expertise in this area. GMPG have been recognised as leaders in the field both in design and CQV testing of these facilities.